Prevounce Health has announced that its Pylo 900-LTE blood pressure monitor is now US Food and Drug Administration (FDA)-cleared and clinically validated for pregnancy use.
Pylo 900-LTE is designed to remotely monitor gestational hypertension, facilitating early detection of preeclampsia and reducing the risk of eclampsia in late pregnancy.
The device will be offered with the Pylo GL1-LTE blood glucometer, the Prevounce care management platform and full logistics services. This will provide a comprehensive solution for maternal health remote patient monitoring (RPM) programmes.
According to Prevounce Health, remote maternal monitoring offers significant cost savings for both healthcare systems and patients.
Prevounce Health founder and CEO Daniel Tashnek said: “Clinicians and patients need new tools in the fight against foetal and maternal mortality.
“Remote patient monitoring has proven to be an effective tool in managing both gestational hypertension and diabetes.
“We’re hopeful our updated remote blood pressure monitor contributes in some small way to healthier mothers and safer pregnancies.”
Prevounce Health provides comprehensive cloud software, cellular-connected devices, and expert services to simplify remote patient monitoring, chronic care management, preventive care, and annual wellness visits.
Its Pylo RPM devices include blood pressure monitors, weight scales, blood glucose meters, and pulse oximeters.
Each device is clinically validated, features 5G/4G-LTE connectivity, and transmits data seamlessly to the Prevounce remote care platform or third-party platforms via an application programming interface (API).
In October 2023, the firm raised $7m in total Series A funding to advance its product, and service offerings and scale its team to meet expanding market demand.
In August this year, the digital health firm launched its first blood oxygen device, Pylo OX1-LTE.
Additionally, in June, Prevounce Health introduced Pylo GL1-LTE for remote blood glucose monitoring.
